BioLineRx BLRX announced today that a Notice of Allowance has been received
from the United States Patent and Trademark Office (USPTO) claiming the
crystalline form of BL-1020, a first-in-class orally available treatment
for schizophrenia. The patent, when granted, will be valid at least
until 2031, without taking into account any possible extension periods,
which is nine years longer than the granted patent coverage previously
reported by the Company. Corresponding patent applications are pending
in Europe, Japan, India, China, Brazil, Mexico, Canada, Australia and
Israel.
"We are extremely pleased with the allowance of the patent covering
BL-1020's crystalline form by the USPTO. There is now a significantly
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in